
Iovance Biotherapeutics Inc (IOVA) - Financial and Strategic SWOT Analysis Review
Description
Iovance Biotherapeutics Inc (IOVA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Iovance Biotherapeutics Inc (Iovance) is a biopharmaceutical company. It focuses on the development and commercialization of novel immunotherapy products for treating various cancers. The company develops products based on its tumor-infiltrating lymphocyte (TIL) technology. Iovance's major products include Amtagvi (lifileucel), an autologous, ready-to-infuse cell therapy indicated for the treatment of melanoma and metastatic cervical cancer, and Proleukin (aldesleukin), an interleukin-2 (IL-2) product used in the Amtagvi treatment regimen. The company's products are primarily used for treating adult patients with unresectable or metastatic melanoma. It operates a manufacturing facility in Philadelphia and a research facility in Tampa, Florida. Iovance is headquartered in San Carlos, California, the US.
Iovance Biotherapeutics Inc Key Recent Developments
Sep 17,2025: Advancing Cancer Research Brings New Hope for Patients Worldwide
Aug 29,2025: Iovance Biotherapeutics to Present at Upcoming Conferences
Jul 15,2025: Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer
Jul 10,2025: Iovance Biotherapeutics Names Marc Theoret as Senior Vice President, Regulatory Strategy
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note:Some sections may be missing if data is unavailable for the company
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Iovance Biotherapeutics Inc (Iovance) is a biopharmaceutical company. It focuses on the development and commercialization of novel immunotherapy products for treating various cancers. The company develops products based on its tumor-infiltrating lymphocyte (TIL) technology. Iovance's major products include Amtagvi (lifileucel), an autologous, ready-to-infuse cell therapy indicated for the treatment of melanoma and metastatic cervical cancer, and Proleukin (aldesleukin), an interleukin-2 (IL-2) product used in the Amtagvi treatment regimen. The company's products are primarily used for treating adult patients with unresectable or metastatic melanoma. It operates a manufacturing facility in Philadelphia and a research facility in Tampa, Florida. Iovance is headquartered in San Carlos, California, the US.
Iovance Biotherapeutics Inc Key Recent Developments
Sep 17,2025: Advancing Cancer Research Brings New Hope for Patients Worldwide
Aug 29,2025: Iovance Biotherapeutics to Present at Upcoming Conferences
Jul 15,2025: Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer
Jul 10,2025: Iovance Biotherapeutics Names Marc Theoret as Senior Vice President, Regulatory Strategy
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note:Some sections may be missing if data is unavailable for the company
Table of Contents
62 Pages
- Section 1 - About the Company
- Iovance Biotherapeutics Inc - Key Facts
- Iovance Biotherapeutics Inc - Key Employees
- Iovance Biotherapeutics Inc - Key Employee Biographies
- Iovance Biotherapeutics Inc - Major Products and Services
- Iovance Biotherapeutics Inc - History
- Iovance Biotherapeutics Inc - Company Statement
- Iovance Biotherapeutics Inc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Section 2 – Company Analysis
- Company Overview
- Iovance Biotherapeutics Inc - Business Description
- Geographical Segment: Rest of World
- Performance
- Geographical Segment: United States
- Performance
- R&D Overview
- Iovance Biotherapeutics Inc - Corporate Strategy
- Iovance Biotherapeutics Inc - SWOT Analysis
- SWOT Analysis - Overview
- Iovance Biotherapeutics Inc - Strengths
- Iovance Biotherapeutics Inc - Weaknesses
- Iovance Biotherapeutics Inc - Opportunities
- Iovance Biotherapeutics Inc - Threats
- Iovance Biotherapeutics Inc - Key Competitors
- Section 3 – Company Financial Ratios
- Financial Ratios - Capital Market Ratios
- Financial Ratios - Annual Ratios
- Performance Chart
- Financial Performance
- Financial Ratios - Interim Ratios
- Financial Ratios - Ratio Charts
- Section 4 – Company’s Lifesciences Financial Deals and Alliances
- Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
- Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
- Iovance Biotherapeutics Inc, Recent Deals Summary
- Section 5 – Company’s Recent Developments
- Sep 17, 2025: Advancing Cancer Research Brings New Hope for Patients Worldwide
- Aug 29, 2025: Iovance Biotherapeutics to Present at Upcoming Conferences
- Jul 15, 2025: Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer
- Jul 10, 2025: Iovance Biotherapeutics Names Marc Theoret as Senior Vice President, Regulatory Strategy
- May 08, 2025: Iovance Biotherapeutics Reports Financial Results and Corporate Updates for First Quarter 2025
- Feb 27, 2025: Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Fourth Quarter and Full Year 2024
- Feb 10, 2025: Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer
- Nov 26, 2024: Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer
- Nov 07, 2024: Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024
- Sep 03, 2024: Iovance Biotherapeutics to Present at Upcoming Conferences
- Section 6 – Appendix
- Methodology
- Ratio Definitions
- About GlobalData
- Contact Us
- Disclaimer
- List of Tables
- Iovance Biotherapeutics Inc, Key Facts
- Iovance Biotherapeutics Inc, Key Employees
- Iovance Biotherapeutics Inc, Key Employee Biographies
- Iovance Biotherapeutics Inc, Major Products and Services
- Iovance Biotherapeutics Inc, History
- Iovance Biotherapeutics Inc, Other Locations
- Iovance Biotherapeutics Inc, Subsidiaries
- Iovance Biotherapeutics Inc, Key Competitors
- Iovance Biotherapeutics Inc, Ratios based on current share price
- Iovance Biotherapeutics Inc, Annual Ratios
- Iovance Biotherapeutics Inc, Annual Ratios (Cont...1)
- Iovance Biotherapeutics Inc, Annual Ratios (Cont...2)
- Iovance Biotherapeutics Inc, Interim Ratios
- Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
- Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
- Iovance Biotherapeutics Inc, Recent Deals Summary
- Currency Codes
- Capital Market Ratios
- Equity Ratios
- Profitability Ratios
- Cost Ratios
- Liquidity Ratios
- Leverage Ratios
- Efficiency Ratios
- List of Figures
- Iovance Biotherapeutics Inc, Performance Chart (2020 - 2024)
- Iovance Biotherapeutics Inc, Ratio Charts
- Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
- Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2019 to YTD 2025
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.